On the morning of November 10th, Baekje Shenzhou (688235) announced that its total operating revenue for the third quarter was 5.624 billion yuan, a year-on-year increase of 111.5%, including product revenue of 4.287 billion yuan, a year-on-year increase of 79.2%; The net profit attributable to the parent company was 1.341 billion yuan, a year-on-year turnaround. In the first three quarters, the company had a net loss attributable to its parent company of 3.878 billion yuan.
Screenshot of Baekje Shenzhou Announcement
Baekje Shenzhou stated that its operating revenue in the first three quarters of 2023 increased by 87.4% compared to the same period last year, mainly due to the sales growth of self-developed products and Anjin authorized products; In addition, we have regained the use of Esperazumab and Bazean& Reg; After obtaining all global commercialization rights, the company recognized the remaining deferred income related to the cooperation and correspondingly increased operating income.
At the same time, the operating profit in the first three quarters of 2023 decreased compared to the same period last year, mainly due to the increase in product revenue and expense management driving the improvement of operating efficiency; In the first three quarters of 2023, the total profit and net profit attributable to the owners of the parent company decreased compared to the same period last year. In addition to the aforementioned factors for reducing operating losses, it was mainly due to non operating income related to the arbitration settlement with BMS.
In the secondary market, as of press release, Baekje Shenzhou fell 3.65% to 145.78 yuan per share.
转播
